CL

Celon Pharma SAWSE Celon Stock Report

Last reporting period 30 Jun, 2024

Updated 21 Oct, 2024

Last price

Market cap $B

0.514

Micro

Exchange

XWAR - Warsaw Stock Exchange

CLN.WA Stock Analysis

CL

Uncovered

Celon Pharma SA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-18/100

Low score

Market cap $B

0.514

Dividend yield

1.08 %

Shares outstanding

51.035 B

Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.

View Section: Eyestock Rating